[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Joshua Woolley, MD, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100551069","phase-2-psilocybin-therapy-for-depression-in-parkinsons-disease-100551069",false,"NCT06455293","Psilocybin Therapy for Depression in Parkinson's Disease","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","PDP2","Inclusion Criteria:\n\n* Age 40 to 80\n* Comfortable speaking and writing in English\n* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an \"on\" phase (time when medication\u002FDBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)\n* Currently experiencing depressive symptoms\n* Able to attend all in-person visits at UCSF as well as virtual visits\n* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating\n\nExclusion Criteria:\n\n* Psychotic symptoms involving loss of insight\n* Significant cognitive impairment\n* Regular use of medications that may have problematic interactions with psilocybin\n* A health condition that makes this study unsafe or unfeasible, determined by study physicians","ALL","40 Years","80 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.",[28,29],"Parkinson Disease","Depression",[28,29,31,32,33],"Psilocybin","Psilocybin therapy","Movement disorder","RECRUITING","2026-08-04",{"date":37,"type":38},"2026-08-07","ACTUAL",{"date":40,"type":38},"2024-08-19",{"date":42,"type":22},"2028-06",{"name":44,"class":45},"Joshua Woolley, MD, PhD","OTHER",""]